Oral Peptide Drug Delivery: Strategies to Overcome Challenges

Peptide Drug Discovery and Development: Translational Research in Academia and Industry

Volumn , Issue , 2011, Pages 71-90

  Hamman, Josias H ^a,b   Steenekamp, Jan H ^b  

^a TSHWANE UNIVERSITY OF TECHNOLOGY   (South Africa)

^b NORTH WEST UNIVERSITY   (South Africa)

Author keywords

Absorption enhancement; Formulation strategies; Paracellular transport; Targeting strategies; Transcellular transport; Transport barrier

Indexed keywords

EID: 84871679525     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527636730.ch3     Document Type: Chapter

References (109)

1. Antosova, Z., Mackova, M., Kral, V., and Macek, T. (2009) Therapeutic application of peptides and proteins: parenteral forever?. Trends Biotechnol., 27 (11), 628-635.
2. Babu, V.R., Patel, P., Mundargi, R.C., Rangaswamy, V., and Aminabhavi, T.M. (2008) Developments in polymeric devices for oral insulin delivery. Expert Opin. Drug Deliv., 5 (4), 403-415.
3. Aungst, B.J. (2000) Intestinal permeation enhancers. J. Pharm. Sci., 89 (4), 429-442.
4. Shaji, J. and Patole, V. (2008) Protein and peptide delivery: oral approaches. Ind. J. Pharm. Sci., 70 (3), 269-277.
5. Lu, Y., Yang, J., and Sega, E. (2006) Issues related to targeted delivery of proteins and peptides. AAPS J, 8 (3), E466-E478.
6. Singh, R., Shailesh, S., and Lillard, J.W. (2008) Past, present and future technologies for oral delivery of therapeutic proteins. J. Pharm. Sci., 97 (7), 2497-2523.
7. Daugherty, A.L. and Mrsny, R.J. (1999) Transcellular uptake mechanisms of the intestinal epithelial barrier: part one. Pharm. Sci. Technol. Today, 2 (4), 144-151.
8. Fasano, A. (1998) Innovative strategies for the oral delivery of drugs and peptides. Trends Biotechnol., 16 (4), 152-157.
9. Salama, N.N., Eddington, N.D., and Fasano, A. (2006) Tight junction modulation and its relationship to drug delivery. Adv. Drug Deliv. Rev., 58 (1), 15-28.
10. +-coupled uphill transport of aminocephalosporins via the intestinal transport system in rabbit intestinal brush-border membranes. J. Biol. Chem., 261 (30), 14130-14134.
11. +-dependent transport mechanism of dipeptide and anionic b-lactam antibiotic ceftibuten in rat intestinal brush-border membrane. J. Pharmacol. Exp. Ther., 289 (1), 66-71.
12. Rodewald, R. and Kraehenbuhl, J.-P. (1984) Receptor-mediated transport of IgG. J. Cell Biol., 99 (1), 159s-164s.
13. Lee, V.H.L. and Yamamoto, A. (1989) Penetration and enzymatic barriers to peptide and protein absorption. Adv. Drug Deliv. Rev., 4 (2), 171-207.
14. Pauletti, G.M., Gangwar, S., Knipp, G.T., Nerurkar, M.M., Okumu, F.W., Tamura, K., Siahaan, T.J., and Borchardt, R.T. (1996) Structural requirements for intestinal absorption of peptide drugs. J. Control. Rel., 41 (1-2), 3-17.
15. Banga, A.K. and Chien, Y.W. (1988) Systemic delivery of therapeutic peptides and proteins. Int. J. Pharm., 48 (1-3), 15-50.
16. Zhou, X.H. and Li Wan Po, A. (1991a) Peptide and protein drugs. I. Therapeutic applications, absorption and parenteral administration. Int. J. Pharm., 75 (2-3), 97-115.
17. Lipka, E., Crison, J., and Amidon, G.L. (1996) Transmembrane transport of peptide type compounds: prospects for oral delivery. J. Control. Rel., 39 (2-3), 121-129.
18. Aungst, B.J., Saitoh, H., Burcham, D.L., Huang, S.-M., Mousa, S.A., and Hussain, M.A. (1996) Enhancement of the intestinal absorption of peptides and non-peptides. J. Control. Rel., 41 (1-2), 19-31.
19. Wang, W., Nema, S., and Teagarden, D. (2010) Protein aggregation-pathways and influencing factors. Int. J. Pharm., 390 (2), 89-99.
20. Van Hoogdalem, E.J., De Boer, A.G., and Breimer, D.D. (1989) Intestinal drug absorption enhancement: an overview. Pharmacol. Ther., 44 (3), 407-443.
21. Fagerholm, U. and Lennernäs, H. (1995) Experimental estimation of the effective unstirred water layer thickness in the human jejunum, and its importance in oral drug absorption. Euro. J. Pharm. Sci., 3 (5), 247-253.
22. Verhoef, J.C., Boddè, H.E., De Boer, A.G., Bouwstra, J.A., Junginger, H.E., Merkus, F.W.H.M., and Breimer, D.D. (1990) Transport of peptide and protein drugs across biological membranes. Eur. J. Drug Metab. Ph., 15 (2), 83-93.
23. Larhed, W.A., Artursson, P., Gråsjö, J., and Björk, E. (1997) Diffusion of drugs in native and purified gastrointestinal mucus. J. Pharm. Sci., 86 (6), 660-665.
24. Norris, D.A., Puri, N., and Sinko, P.J. (1998) The effect of physical barriers and properties on the oral absorption of particulates. Adv. Drug Deliv. Rev., 34 (2-3), 135-154.
25. Takatsuka, S., Kitazawa, T., Morita, T., Horikiri, Y., and Yoshino, H. (2006) Enhancement of the intestinal absorption of poorly absorbed hydrophilic compounds by simultaneous use of mucolytic agent and non-ionic surfactant. Eur. J. Pharm. Biopharm., 62 (1), 52-58.
26. Schipper, N.G.M., Vårum, K.M., Stenberg, P., Ocklind, G., Lennernäs, H., and Artursson, P. (1999) Chitosans as absorption enhancers of poorly absorbable drugs 3: influence of mucus on absorption enhancement. Eur. J. Pharm. Sci., 8 (4), 335-343.
27. Madara, J.L. and Trier, J.S. (1987) Functional morphology of the mucosa of the small intestine, in Physiology of the Gastrointestinal Tract, 2nd edn (ed. L.R. Johnson), Raven Press, New York, pp. 1209-1249.
28. Muranishi, M. and Yamamoto, Y. (1994) Mechanisms of absorption enhancement through gastrointestinal epithelium, in Drug Absorption Enhancement: Concepts, Possibilities, Limitations and Trends (ed. A.G. de Boer), Harwood Academic Press, pp. 66-100.
29. Washington, N., Washington, C., and Wilson, C.G. (eds) (2001) Physiological Pharmaceutics: Barriers to Drug Absorption, 2nd ed, Taylor and Francis, New York, pp. 312.
30. Sha'afi, R.I., Gary-Bobo, C.M., and Solomon, A.K. (1971) Permeability of red blood cell membranes to small hydrophilic and lipophilic solutes. J. Gen. Physiol., 58, 238-258.
31. Ward, P.D., Tippin, T.K., and Thakker, D.R. (2000) Enhancing paracellular permeability by modulating epithelial tight junctions. Pharm. Sci. Technol. Today, 3 (10), 346-358.
32. Salamat-Miller, N. and Johnston, T.P. (2005) Current strategies used to enhance the paracellular transport of therapeutic polypeptides across the intestinal epithelium. Int. J. Pharm., 294 (1-2), 201-216.
33. Langguth, P., Bohner, V., Heizmann, J., Merkle, H.P., Wolffram, S., Amidon, G.L., and Yamashita, S. (1997) The challenge of proteolytic enzymes in intestinal peptide delivery. J. Control. Rel., 46 (1-2), 39-57.
34. Carino, G.P. and Mathiowitz, E. (1999) Oral insulin delivery. Adv. Drug Deliv. Rev., 35 (2-3), 249-257.
35. Aungst, B.J. (1993) Novel formulation strategies for improving oral bioavailability of drugs with poor membrane permeation or presystemic metabolism. J. Pharm. Sci., 82 (10), 979-987.
36. Zhou, X.H. and Li Wan Po, A. (1991) Peptide and protein drugs. II. Nonparenteral routes of delivery. Int. J. Pharm., 75 (2-3), 117-130.
37. Zhou, X.H. (1994) Overcoming enzymatic and absorption barriers to non-parenterally administered protein and peptide drugs. J. Control. Rel., 29 (3), 239-252.
38. Alpers, D.H. (1987) Digestion and absorption of carbohydrates and proteins, in Physiology of the Gastrointestinal Tract, 2nd edn (ed. L.R. Johnson), Raven Press, New York, pp. 1469-1487.
39. Bernkop-Schnürch, A. (1998) The use of inhibitory agents to overcome the enzymatic barrier to perorally administered therapeutic peptides and proteins. J. Control. Rel., 52 (1-2), 1-16.
40. Gardner, M.G. (1979) Superficial or membrane digestion of peptides in dinitrophenol-inhibited rat small intestine. Clin. Sci., 57 (2), 217-220.
41. Burton, P.S., Goodwin, J.T., Conradi, R.A., Ho, N.F.H., and Hilgers, A.R. (1997) In vitro permeability of peptidomimetic drugs: the role of polarized efflux pathways as additional barriers to absorption. Adv. Drug Deliv. Rev., 23 (1-3), 143-156.
42. Hunter, J. and Hirst, B.H. (1997) Intestinal secretion of drugs. The role of P-glycoprotein and related drug efflux systems in limiting oral drug absorption. Adv. Drug Deliv. Rev., 25 (2-3), 129-157.
43. Chan, L.M.S., Lowes, S., and Hirst, B. H. (2004) The ABC's of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability. Eur. J. Pharm. Sci., 21 (1), 25-51.
44. Benet, L.Z., Wu, C.-Y., Hebert, M.F., and Wacher, V.J. (1996) Intestinal drug metabolism and antitransport processes: a potential paradigm shift in oral drug delivery. J. Control. Rel., 39 (2-3), 139-143.
45. Zheng, Y., Qui, Y., Fu Lu, M., Hoffman, D., and Reiland, T.L. (1999) Permeability and absorption of leuprolide from various intestinal regions in rabbits and rats. Int. J. Pharm., 185 (1), 83-92.
46. Morishita, I., Morishita, M., Takayama, K., Machida, Y., and Nagai, T. (1993) Enteral insulin delivery by microspheres in 3 different formulations using Eudragit L100 and S100. Int. J. Pharm., 91 (1), 29-37.
47. Shantha Kumar, T.R., Soppimath, K., and Nachaegari, S.K. (2006) Novel delivery technologies for protein and peptide therapeutics. Curr. Pharm. Biotechnol., 7, 261-276.
48. Kagan, L. and Hoffman, A. (2008) Systems for region selective drug delivery in the gastrointestinal tract: biopharmaceutical considerations. Exp. Opin. Drug Deliv., 5 (6), 681-692.
49. Ziv, E., Lior, O., and Kidron, M. (1987) Absorption of protein via the intestinal wall. A quantitative model. Biochem. Pharmacol., 36 (7), 1035-1039.
50. Touitou, E. (1992) Enhancement of intestinal peptide absorption. J. Control. Rel., 21, 139-144.
51. Carino, G.P. and Mathiowitz, E. (1999) Oral insulin delivery. Adv. Drug Deliv. Rev., 35, 249-257.
52. Muranishi, S. (1990) Absorption enhancers. Crit. Rev. Ther. Drug Carrier Syst., 7 (1), 1-33.
53. Whitehead, K. and Mitragotri, S. (2008) Mechanistic analysis of chemical permeation enhancers for oral drug delivery. Pharm. Res., 25 (6), 1412-1419.
54. Fix, J.A. (1996) Strategies for delivery of peptides utilising absorption enhancing agents. J. Pharm. Sci., 85 (12e), 1282-1285.
55. LeCluyse, E.L. and Sutton, S.C. (1997) In vitro models for selection of development candidates. Permeability studies to define mechanisms of absorption enhancement. Adv. Drug Deliv. Rev., 23, 163-183.
56. Catalioto, R.-M., Triolo, A., Giuliani, S., Altamura, M., Evangelista, S., and Maggi, C.A. (2008) Increased paracellular absorption by bile salts and P-glycoprotein stimulated efflux of otilonium bromide in Caco-2 cells monolayers as a model of intestinal barrier. J. Pharm. Sci., 97 (9), 4087-4100.
57. Nerurkar, M.M., Ho, N.F.H., Burton, P.S., Vidmar, T.J., and Borchardt, R.T. (1997) Mechanistic roles of neutral surfactants on concurrent polarized and passive membrane transport of a model peptide in Caco-2 cells. J. Pharm. Sci., 86 (7), 813-821.
58. Pauletti, G.M., Gangwar, S., Siahaan, T.J., Aubè, J., and Borchardt, R.T. (1997) Improvement of oral peptide bioavailability: peptidomimetics and prodrug strategies. Adv. Drug Deliv. Rev., 27, 235-256.
59. Xia, W.J. and Onyuksel, H. (2000) Mechanistic studies on surfactant induced membrane permeability enhancement. Pharm. Res., 17 (5), 612-618.
60. Kotzè, A.F., De Leeuw, B.J., Lueen, H. L., De Boer, (A)Bert.G., Verhoef, J.C., and Junginger, H.E. (1997) Chitosans for enhanced delivery of therapeutic peptides across intestinal epithelia: in vitro evaluation in Caco-2 cell monolayers. Int. J. Pharm., 159, 243-253.
61. Kotzè, A.F., Luessen, H.L., De Boer, A. G., Verhoef, J.C., and Junginger, H.E. (1998) Chitosan for enhanced intestinal permeability: prospects for derivatives soluble in neutral and basic environments. Eur. J. Pharm. Sci., 7, 145-151.
62. Thanou, M., Verhoef, J.C., and Junginger, H.E. (2001) Oral drug absorption enhancement by chitosan and its derivatives. Adv. Drug Deliv. Rev., 52, 117-126.
63. Borchard, G., Luessen, H.L., De Boer, A.G., Verhoef, J.C., Lehr, C.-M., and Junginger, J.E. (1996) The potential of mucoadhesive polymers in enhancing intestinal peptide drug absorption. III: effects of chitosan glutamate and carbomer on epithelial tight junctions in vitro. J. Control. Rel., 39, 131-138.
64. Di Colo, G., Zambito, Y., and Zaino, C. (2007) Polymeric enhancers of mucosal epithelia permeability: synthesis, transepithelial penetration enhancing properties, mechanism of action, safety issues. J. Pharm. Sci., 97, 1-29.
65. Werle, M. (2008) Natural and synthetic polymers as inhibitors of drug efflux pumps. Pharm. Res., 25 (3), 500-511.
66. Cano-Cebriàn, M.J., Zornosa, T., Granero, L., and Polache, A. (2005) Intestinal absorption enhancement via the paracellular route by fatty acids, chitosans and others: a target for drug delivery. Curr. Drug Deliv., 2, 9-22.
67. Maher, S., Wang, X., Bzik, V., McClean, S., and Brayden, D.J. (2009) Evaluation of intestinal absorption and mucosal toxicity using two promoters. II. Rat instillation and perfusion studies. Eur. J. Pharm. Sci., 38, 301-311.
68. Johnson, P.H., Frank, D., and Costantino, H.R. (2008) Discovery of tight junction modulators: significance for drug development and delivery. Drug Discov. Today, 13 (5/6), 261-267.
69. Fasano, A. (1998) Novel approaches for oral delivery of macromolecules. J. Pharm. Sci., 87 (11), 1351-1356.
70. Cox, D.S., Raje, S., Gao, H., Salama, N.N., and Edington, N.D. (2002) Enhanced permeability of molecular weight markers and poorly bioavailable compounds across Caco-2 cell monolayers using the absorption enhancer, zonula occludens toxin. Pharm. Res., 19 (11), 1680-1688.
71. Salama, N.N., Eddington, N.D., and Fasano, A. (2006) Tight junction modulation and its relationship to drug delivery. Adv. Drug Deliv. Rev., 58, 15-28.
72. Matsuhisa, K., Kondoh, M., Takahashi, A., and Yagi, K. (2009) Tight junction modulator and drug delivery. Exp. Opin. Drug Deliv., 6 (5), 509-515.
73. Maher, S., Devocelle, M., Ryan, S., McClean, S., and Brayden, D.J. (2010) Impact of amino acid replacements on in vitro permeation enhancement and cytotoxicity of the intestinal absorption promoter, melittin. Int. J. Pharm., 387, 154-160.
74. Fuller, E., Duckham, C., and Wood, E. (2007) Disruption of epithelial tight junctions by yeast enhances the paracellular delivery of a model protein. Pharm. Res., 24 (1), 37-47.
75. Chen, W., Lu, Z., Viljoen, A., and Hamman, J. (2009) Intestinal drug transport enhancement by Aloe vera. Planta Medica, 75, 587-595.
76. Lu, Z., Chen, W., Viljoen, A., and Hamman, J.H. (2010) Effect of sinomenine on the in vitro intestinal epithelial transport of selected compounds. Phytother. Res., 24, 211-218.
77. Swenson, E.S., Milisen, W.B., and Curatolo, W. (1994) Intestinal permeability enhancement: efficacy, acute local toxicity and reversibility. Pharm. Res., 11 (8), 1132-1142.
78. Fasano, A. (1998) Innovative strategies for the oral delivery of drugs and peptides. Trends Biotechnol., 16, 152-157.
79. Hamman, J.H., Schultz, C.M., and Kotzè, A.F. (2003) N-trimethyl chitosan chloride: optimum degree of quaternization for drug absorption enhancement across epithelial cells. Drug Develop. Ind. Pharm., 29 (2), 161-172.
80. Oliyai, R. (1996) Prodrugs of peptides and peptidomimetics for improved formulation and delivery. Adv. Drug Deliv. Rev., 19, 275-286.
81. Borchardt, R.T. (1999) Optimizing oral absorption of peptides using prodrug strategies. J. Control. Rel., 62, 231-238.
82. Khandare, J. and Minko, T. (2006) Polymer drug conjugates: progress in polymeric prodrugs. Prog. Polym. Sci., 31, 359-397.
83. Ali, M. and Manolios, N. (2002) Peptide delivery systems. Lett. Peptide Sci., 8, 289-294.
84. Bailon, P. and Won, C.-Y. (2009) PEGmodified biopharmaceuticals. Exp. Opin. Drug Deliv., 6 (1), 1-6.
85. Owens, D.R., Zinman, B., and Bolli, G. (2003) Alternative routes of insulin delivery. Diabetic Med., 20, 886-898.
86. Cefalu, W.T. (2004) Concept, strategies, and feasibility of noninvasive insulin delivery. Diabetes Care, 27, 239-46.
87. Herce, H.D. and Garcia, A.E. (2007) Cell penetrating peptides: how do they do it?. J. Biol. Phys., 33, 345-356.
88. Snyder, E.L. and Dowdy, S.F. (2004) Cell penetrating peptides in drug delivery. Pharm. Res., 21 (3), 389-393.
89. Patel, L.N., Zaro, J.L., and Shen, W.-C. (2007) Cell penetrating peptides: intracellular pathways and pharmaceutical perspectives. Pharm. Res., 24 (11), 1977-1992.
90. Hassane, F.S., Saleh, A.F., Abes, R., Gait, M.J., and Lebleu, B. (2010) Cell penetrating peptides: overview and applications to the delivery of oligonucleotides. Cell. Mol. Life Sci., 67, 715-726.
91. Chourasia, M.K. and Jain, S.K. (2004) Polysaccharides for colon targeted drug delivery. Drug Deliv., 11, 129-148.
92. Roldo, M., Barbu, E., Brown, J.F., Laight, D.W., Smart, J.D., and Tsibouklis, J. (2007) Azo compounds in colon-specific drug delivery. Exp. Opin. Drug Deliv., 4 (5), 547-560.
93. Mandava, N., Oberoi, R.K., Minocha, M., and Mitra, A.K. (2010) Transporter targeted drug delivery. J. Drug Deliv. Sci. Technol., 20 (2), 89-99.
94. Majumdar, S., Duvvuri, S., and Mitra, A.K. (2004) Membrane transporter/receptor-targeted prodrug design: strategies for human and veterinary drug development. Adv. Drug Deliv. Rev., 56, 1437-1452.
95. Steffansen, B., Nielsen, C.U., Brodin, B., Eriksson, A.H., Andersen, R., and Frokjaer, S. (2004) Intestinal solute carriers: an overview of trends and strategies for improving oral drug absorption. Eur. J. Pharm. Sci., 21, 3-16.
96. Russell-Jones, G.J. (2001) The potential use of receptor-mediated endocytosis for oral drug delivery. Adv. Drug Deliv. Rev., 46, 59-73.
97. Russel-Jones, G.J., Arthur, L., and Walker, H. (1999) Vitamin B12-mediated transport of nanoparticles across Caco-2 cells. Int. J. Pharm., 179, 247-255.
98. Yang, Y.-Y., Wang, Y., Powell, R., and Chan, P. (2006) Polymer core-shell nanoparticles for therapeutics. Clin. Exp. Pharmacol. Physiol., 33, 557-562.
99. Yamanaka, Y.J. and Leong, K.W. (2008) Engineering strategies to enhance nanoparticle-mediated oral delivery. J. Biomater. Sci.-Polym. Ed., 19 (12), 1549-1570.
100. Des Rieux, A., Fievez, V., Garinot, M., Schneider, Y.-J., and Preat, V. (2006) Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. J. Control. Rel., 116, 1-27.
101. Balasubramanian, V., Onaca, O., Enea, R., Hughes, D.W., and Palivan, C.G. (2010) Protein delivery: from conventional drug delivery carriers to polymeric nanoreactors. Exp. Opin. Drug Deliv., 7 (1), 63-78.
102. Napier, M.E. and Desimone, J.M. (2007) Nanoparticle drug delivery platform. Polym. Rev., 47, 321-327.
103. Bernkop-Schnürch, A. (1998) The use of inhibitory agents to overcome the enzymatic barrier to perorally administered therapeutic peptides and proteins. J. Control. Rel., 52, 1-16.
104. Gabor, F., Bogner, E., Weissenboeck, A., and Wirth, M. (2004) The lectin-cell interaction and its implications to intestinal lectin-mediated drug delivery. Adv. Drug Deliv. Rev., 56, 459-80.
105. Peppas, N.A. and Huang, Y. (2004) Nanoscale technology of mucoadhesive interactions. Adv. Drug Deliv. Rev., 56, 1675-1687.
106. Vasir, J.K., Tambwekar, K., and Garg, S. (2003) Bioadhesive microspheres as a controlled drug delivery system. Int. J. Pharm., 255, 13-32.
107. Bernkop-Schnürch, A. (2005) Mucoadhesive systems in oral drug delivery. Drug Discov. Today: Technol., 2 (1), 83-87.
108. Kompella, U.B. and Lee, V.H.L. (2001) Delivery systems for penetration enhancement of peptide and protein drugs: design considerations. Adv. Drug Deliv. Rev., 46, 211-245.
109. Peppas, N.A., Thomas, J.B., and McGinty, J. (2009) Molecular aspects of mucoadhesive carrier development for drug delivery and improved absorption. J. Biomater. Sci., 20, 1-20.